Gratifyingly, the DESTINY-Breast 01, EMILIA, LANDSCAPE, HER2CLIMB, and NALA study respectively confirmed that DS-8201, T-DM1, lapatinib, tucatinib, and neratinib are effective in HER2-positive BC with CNS metastasis. This evidence concerns the gene ERBB2 and breast cancer.